RedHill Biopharma Ltd.
RDHL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 23.2% | -89.4% | -27.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.3% | 47% | 46.1% | 42.4% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -94.4% | 402.3% | -35.9% | -73.5% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -102.8% | 366.2% | -116% | -114% |
| EPS Diluted | -7 | 46 | -600 | -1,000 |
| % Growth | -115.2% | 107.7% | 40% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |